Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1 R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms.

Copyright Nasdaq. Minimum 15 minutes delayed.

Events

More events are coming soon.
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology

REDWOOD CITY, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic

Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the

Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock

REDWOOD CITY, Calif. , Jan. 24, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the pricing of the Company’s initial public offering of 7,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts.